These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 2519837)
1. Efficacy of idiotypic vaccination in mice bearing B-cell lymphoma. Khan NA In Vivo; 1989; 3(2):117-9. PubMed ID: 2519837 [TBL] [Abstract][Full Text] [Related]
2. Idiotypic vaccination as a treatment for a B cell lymphoma. George AJ; Folkard SG; Hamblin TJ; Stevenson FK J Immunol; 1988 Sep; 141(6):2168-74. PubMed ID: 3049800 [TBL] [Abstract][Full Text] [Related]
3. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. George AJ; Tutt AL; Stevenson FK J Immunol; 1987 Jan; 138(2):628-34. PubMed ID: 3491853 [TBL] [Abstract][Full Text] [Related]
4. Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma. Weiner GJ; Kaminski MS J Immunol; 1990 Mar; 144(6):2436-45. PubMed ID: 1690244 [TBL] [Abstract][Full Text] [Related]
5. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model. Kwak LW; Campbell M; Levy R Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139 [TBL] [Abstract][Full Text] [Related]
6. Molecules recognized by anti-idiotypic monoclonal antibodies to the B cell lymphoma, BCL1. Tamura GS; McGrath MS; Weissman IL J Mol Cell Immunol; 1987; 3(4):243-53. PubMed ID: 3509925 [TBL] [Abstract][Full Text] [Related]
7. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth. Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709 [TBL] [Abstract][Full Text] [Related]
8. Idiotype vaccination leads to the emergence of a stable surface Ig-negative variant of the mouse lymphoma BCL1, with different growth characteristics. George AJ; Spellerberg MB; Stevenson FK J Immunol; 1988 Mar; 140(5):1695-701. PubMed ID: 3162250 [TBL] [Abstract][Full Text] [Related]
9. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Ruffini PA; Neelapu SS; Kwak LW; Biragyn A Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812 [TBL] [Abstract][Full Text] [Related]
10. Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma. Weiner GJ; Kaminski MS J Immunol; 1989 Jan; 142(1):343-51. PubMed ID: 2783325 [TBL] [Abstract][Full Text] [Related]
11. B-cell malignancy and monoclonal gammopathy, and idiotype of cell surface and serum immunoglobulin. Sugai S; Takiguchi T; Hirose Y; Konaka Y; Shimizu S; Konda S Jpn J Clin Oncol; 1983 Sep; 13(3):533-42. PubMed ID: 6417376 [TBL] [Abstract][Full Text] [Related]
12. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. Campbell MJ; Carroll W; Kon S; Thielemans K; Rothbard JB; Levy S; Levy R J Immunol; 1987 Oct; 139(8):2825-33. PubMed ID: 3498771 [TBL] [Abstract][Full Text] [Related]
13. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. Kaminski MS; Kitamura K; Maloney DG; Levy R J Immunol; 1987 Feb; 138(4):1289-96. PubMed ID: 3492546 [TBL] [Abstract][Full Text] [Related]
14. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Kwak LW; Young HA; Pennington RW; Weeks SD Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293 [TBL] [Abstract][Full Text] [Related]
15. Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. King CA; Wills MR; Hamblin TJ; Stevenson FK Cell Immunol; 1993 Apr; 147(2):411-24. PubMed ID: 8095858 [TBL] [Abstract][Full Text] [Related]
16. Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination. Cesco-Gaspere M; Zentilin L; Giacca M; Burrone OR Scand J Immunol; 2008 Jul; 68(1):58-66. PubMed ID: 18482206 [TBL] [Abstract][Full Text] [Related]
17. Rejection of tumors of the B cell lineage by idiotype-vaccinated mice. Haimovich J; Kukulansky T; Weissman B; Hollander N Cancer Immunol Immunother; 1999 Feb; 47(6):330-6. PubMed ID: 10203063 [TBL] [Abstract][Full Text] [Related]
18. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465 [TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014 [TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies raised against the idiotype of the murine B cell lymphoma, BCL1 act primarily with heavy chain determinants. George AJ; McBride HM; Glennie MJ; Smith LJ; Stevenson FK Hybridoma; 1991 Apr; 10(2):219-27. PubMed ID: 1908435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]